celiprolol has been researched along with Heart Failure in 11 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed to investigate, in patients with severe heart failure, the dose-dependent acute hemodynamic effects of celiprolol versus those of esmolol." | 9.09 | Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol. ( Baumann, G; Doerffel, W; Felix, SB; Kieback, A; Stangl, K; Stangl, V; Staudt, A; Wernecke, KD, 2001) |
| "This study examines the acute effects of two differing beta adrenergic blocking agents (metoprolol and a third generation vasodilating beta blocker) on plasma concentrations of atrial natriuretic factor (ANF), brain (ventricular) natriuretic factor (BNF), and haemodynamic variables in patients with heart failure." | 9.08 | Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. ( Chan, SK; Chan, WW; Hung, YT; Raymond, K; Sanderson, JE; Shum, IO; Woo, KS, 1995) |
| "To determine whether a third generation vasodilating beta blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure." | 9.08 | Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. ( Chan, KW; Chan, SK; Chan, WM; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yu, CM, 1998) |
| "Both celiprolol and candesartan showed cardioprotective effects in this heart failure model." | 7.73 | Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure. ( Hayashi, T; Kitaura, Y; Matsumura, Y; Mori, T; Ohkita, M; Okuda, N; Shimomura, H; Sohmiya, K; Yoshikawa, J; Yoshiyama, M, 2005) |
| "These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure." | 7.72 | Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "To assess the effects of celiprolol, which is a selective beta1-antagonist with vasodilating properties, on chronic heart failure in the cardiomyopathic hamster UM-X7." | 7.70 | Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure. ( Matsuzaki, M; Nakamura, Y; Ohkusa, T; Ryoke, T; Tanaka, N, 1998) |
| "Impaired insulin sensitivity has been linked with chronic heart failure (CHF)." | 6.69 | Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. ( Huupponen, R; Malminiemi, K; Pere, E; Pietilä, M; Pulkki, K; Rouru, J; Voipio-Pulkki, LM, 2000) |
| "In this study, the effect of celiprolol (beta-1-antagonist with beta-2-agonistic activity) on hemodynamic and electrocardiographic parameters of patients with congestive heart failure due to ischemic (iCMP) and non-ischemic (niCMP) origin should be evaluated." | 5.09 | Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy. ( Hennersdorf, MG; Perings, C; Vester, EG, 1999) |
| "The present study was designed to investigate, in patients with severe heart failure, the dose-dependent acute hemodynamic effects of celiprolol versus those of esmolol." | 5.09 | Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol. ( Baumann, G; Doerffel, W; Felix, SB; Kieback, A; Stangl, K; Stangl, V; Staudt, A; Wernecke, KD, 2001) |
| "This study examines the acute effects of two differing beta adrenergic blocking agents (metoprolol and a third generation vasodilating beta blocker) on plasma concentrations of atrial natriuretic factor (ANF), brain (ventricular) natriuretic factor (BNF), and haemodynamic variables in patients with heart failure." | 5.08 | Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. ( Chan, SK; Chan, WW; Hung, YT; Raymond, K; Sanderson, JE; Shum, IO; Woo, KS, 1995) |
| "To determine whether a third generation vasodilating beta blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure." | 5.08 | Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. ( Chan, KW; Chan, SK; Chan, WM; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yu, CM, 1998) |
| "Both celiprolol and candesartan showed cardioprotective effects in this heart failure model." | 3.73 | Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure. ( Hayashi, T; Kitaura, Y; Matsumura, Y; Mori, T; Ohkita, M; Okuda, N; Shimomura, H; Sohmiya, K; Yoshikawa, J; Yoshiyama, M, 2005) |
| "These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure." | 3.72 | Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "To assess the effects of celiprolol, which is a selective beta1-antagonist with vasodilating properties, on chronic heart failure in the cardiomyopathic hamster UM-X7." | 3.70 | Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure. ( Matsuzaki, M; Nakamura, Y; Ohkusa, T; Ryoke, T; Tanaka, N, 1998) |
| "Impaired insulin sensitivity has been linked with chronic heart failure (CHF)." | 2.69 | Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. ( Huupponen, R; Malminiemi, K; Pere, E; Pietilä, M; Pulkki, K; Rouru, J; Voipio-Pulkki, LM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liao, Y | 1 |
| Asakura, M | 1 |
| Takashima, S | 1 |
| Ogai, A | 1 |
| Asano, Y | 1 |
| Shintani, Y | 1 |
| Minamino, T | 1 |
| Asanuma, H | 1 |
| Sanada, S | 1 |
| Kim, J | 1 |
| Kitamura, S | 1 |
| Tomoike, H | 1 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| Mori, T | 1 |
| Hayashi, T | 1 |
| Sohmiya, K | 1 |
| Okuda, N | 1 |
| Shimomura, H | 1 |
| Ohkita, M | 1 |
| Matsumura, Y | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Kitaura, Y | 1 |
| Sanderson, JE | 3 |
| Chan, WW | 1 |
| Hung, YT | 1 |
| Chan, SK | 2 |
| Shum, IO | 1 |
| Raymond, K | 2 |
| Woo, KS | 3 |
| Nakamura, Y | 1 |
| Ryoke, T | 1 |
| Tanaka, N | 1 |
| Ohkusa, T | 1 |
| Matsuzaki, M | 1 |
| Yu, CM | 1 |
| Yeung, LY | 2 |
| Chan, WM | 1 |
| Chan, KW | 1 |
| Chan, S | 1 |
| Tomlinson, B | 1 |
| Kay, R | 1 |
| Bernardi, L | 1 |
| Hennersdorf, MG | 1 |
| Perings, C | 1 |
| Vester, EG | 1 |
| Pietilä, M | 1 |
| Malminiemi, K | 1 |
| Huupponen, R | 1 |
| Rouru, J | 1 |
| Pulkki, K | 1 |
| Pere, E | 1 |
| Voipio-Pulkki, LM | 1 |
| Witchitz, S | 1 |
| Cohen-Solal, A | 1 |
| Dartois, N | 1 |
| Weisslinger, N | 1 |
| Juste, K | 1 |
| Darmon, JY | 1 |
| Felix, SB | 1 |
| Stangl, V | 1 |
| Kieback, A | 1 |
| Doerffel, W | 1 |
| Staudt, A | 1 |
| Wernecke, KD | 1 |
| Baumann, G | 1 |
| Stangl, K | 1 |
| Strein, K | 1 |
| Sponer, G | 1 |
1 review available for celiprolol and Heart Failure
| Article | Year |
|---|---|
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Fa | 1990 |
7 trials available for celiprolol and Heart Failure
| Article | Year |
|---|---|
Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.
Topics: Adrenergic beta-Antagonists; Atrial Natriuretic Factor; Celiprolol; Double-Blind Method; Female; Hea | 1995 |
Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Celiprolol; Chi-Square Distribution; Double | 1998 |
Effect of beta-blockade on baroreceptor and autonomic function in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Autonomic Nervous System; Blood Pressure; C | 1999 |
Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiac Catheterization; Cardiomyopathies; Ca | 1999 |
Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Celiprolol; Cholesterol, HDL; Cholesterol, LDL; Exercise; Female; Heart | 2000 |
Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group.
Topics: Adrenergic beta-Antagonists; Adult; Celiprolol; Double-Blind Method; Female; Heart Failure; Humans; | 2000 |
Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Celiprolol; Dose-Response Relationship, Drug; Half-Life; H | 2001 |
3 other studies available for celiprolol and Heart Failure
| Article | Year |
|---|---|
Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Celiprol | 2004 |
Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Celiprolol; Disease Models, An | 2005 |
Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Body Weight; C | 1998 |